Back

Thiazides attenuate the diuretic response to pecavaptan, a dual vasopressin receptor antagonist, in hospitalized heart failure patients

10 May 2026 (10:30 - 11:15)
Organised by: Logo
Congress Presentation Part of: Navigating the cardio-renal syndrome (2) Pharmacotherapy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Mr Daan Ceelen

University Medical Centre Groningen, Groningen (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
Predicting diuretic resistance without urine output in acute heart failure
Mrs E. Vice (Atlanta, US)
Abstract Slides Video
Presentation thumbnail
Renal safety of a natriuresis-guided diuretic strategy in hospitalised heart failure
Doctor S. Singh (Hartford, US)
Abstract Slides Video
Presentation thumbnail
Sustained low-efficiency dialysis for refractory congestion in advanced cardiorenal syndrome: haemodyamics and weight reduction analysis
Doctor G. Mihelcic (London, GB)
Abstract Slides Video
Presentation thumbnail
Hyperkalemia incidence and recurrence among patients with heart failure - predictors and temporal trends
Doctor F. Lindberg (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Navigating the cardio-renal syndrome (2)

The Event

Event poster

Heart Failure 2026

10 May 2026 10:30 CET
You may be interested in
thumbnail
Congress Presentation
Combination therapy: thiazides, acetazolamide, HSS, and SGLT2i
thumbnail
Congress Presentation
Diuresis efficacy in ambulatory congested heart failure patients: Intra -patient comparison of three diuretic regimens (DEA-HF)
thumbnail
Congress Presentation
Renal response to a dual vasopressin antagonist in acute heart failure: a post-hoc analysis from the AVANTI trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources